<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Leung YKS</submitter><funding>Swiss National Science Foundation</funding><funding>Clinical Research Priority Program of the University of Zurich for the CRPP ‘Precision medicine for bacterial infections’</funding><pagination>dlab041</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8209986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>3(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Optimal timing for rifampicin combination therapy in patients with staphylococcal vascular graft/endograft infection (S-VGEI) is unknown. Experts recommend adding rifampicin after lowering bacterial load by surgery and wound closure.&lt;h4>Objectives&lt;/h4>To assess predictors of rifampicin resistance among staphylococci isolated from patients in the Vascular Graft Infection Cohort Study.&lt;h4>Methods&lt;/h4>We included prospective patients with S-VGEI diagnosis from 1 January 2002 to 30 June 2020. We retrospectively assessed determinants of rifampicin resistance using exact logistic regression and described survival with Kaplan-Meier curves.&lt;h4>Results&lt;/h4>We analysed 513 &lt;i>Staphylococcus&lt;/i> spp. among 143 predominantly male (82%) patients with a median age of 68 years (IQR 60-</pubmed_abstract><journal>JAC-antimicrobial resistance</journal><pubmed_title>Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endograft infections.</pubmed_title><pmcid>PMC8209986</pmcid><funding_grant_id>320030</funding_grant_id><funding_grant_id>320030_184918/1</funding_grant_id><funding_grant_id>184918</funding_grant_id><pubmed_authors>Zimmermann A</pubmed_authors><pubmed_authors>Zbinden R</pubmed_authors><pubmed_authors>Ledergerber B</pubmed_authors><pubmed_authors>Brugger SD</pubmed_authors><pubmed_authors>Leung YKS</pubmed_authors><pubmed_authors>Zinkernagel AS</pubmed_authors><pubmed_authors>Mestres CA</pubmed_authors><pubmed_authors>Eberhard N</pubmed_authors><pubmed_authors>Vascular Graft Cohort Study</pubmed_authors><pubmed_authors>Rancic Z</pubmed_authors><pubmed_authors>Hasse B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endograft infections.</name><description>&lt;h4>Background&lt;/h4>Optimal timing for rifampicin combination therapy in patients with staphylococcal vascular graft/endograft infection (S-VGEI) is unknown. Experts recommend adding rifampicin after lowering bacterial load by surgery and wound closure.&lt;h4>Objectives&lt;/h4>To assess predictors of rifampicin resistance among staphylococci isolated from patients in the Vascular Graft Infection Cohort Study.&lt;h4>Methods&lt;/h4>We included prospective patients with S-VGEI diagnosis from 1 January 2002 to 30 June 2020. We retrospectively assessed determinants of rifampicin resistance using exact logistic regression and described survival with Kaplan-Meier curves.&lt;h4>Results&lt;/h4>We analysed 513 &lt;i>Staphylococcus&lt;/i> spp. among 143 predominantly male (82%) patients with a median age of 68 years (IQR 60-</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-18T19:15:25.713Z</modification><creation>2022-02-10T18:01:00.829Z</creation></dates><accession>S-EPMC8209986</accession><cross_references><pubmed>34223108</pubmed><doi>10.1093/jacamr/dlab041</doi></cross_references></HashMap>